Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
Status:
Completed
Trial end date:
2017-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy
(carboplatin and gemcitabine as second line chemotherapy) may result in prolongation of
progression free survival (PFS).